Inactive

Continuation of SF-1449, Block 3: The following information shall be entered by the Contracting Officer at the time of contract award according to the timeframes specified in this solicitation s Secti... Continuation of SF-1449, Block 3: The following information shall be entered by the Contracting Officer at the time of contract award according to the timeframes specified in this solicitation s Section B, Scope of Contract, Section 1.4 Contract Effective Date, Implementation Period, and Ordering Period. Contract Award/Effective Date: ___________________ Implementation Period: __________________________ Ordering Period (Base Year): _____________________ Offerors shall not enter information into the above fields. Continuation of SF-1449, Blocks 19 through 24: To be considered for award, offerors must submit a price for line item 1A, or 1B, or 1C for the base year and all four option years. One award will be made for line item 1A, or 1B, or 1C for the base year and all four option years. Offered prices shall not exceed two decimal places. The price evaluation will be completed by multiplying the proposed BTK Inhibitors (Ibrutinib/Acalabrutinib/Zanubrutinib) price by the number of units per day required per patient to calculate a cost per day. This cost per day will then be multiplied by the estimated number of patients (a total of 2,444 for all participating agencies) for the proposed product and 365 (days per year) to calculate a total cost per year. The required number of units per patient per day are listed in the table for each item (1A, 1B, 1C) in the Schedule of Supplies and Attachment B of this solicitation. This method of price evaluation will ensure that the prices of proposed products can evaluated accurately and equitably. Unit prices offered shall not exceed two decimal places. The Government intends to evaluate offers and award a contract without discussions with offerors. However, the Government reserves the right to conduct discussions if determined by the Contracting Officer to be necessary. The awarded product will be the only agent listed on the VA National Formulary for Chronic Lymphocytic Leukemia (CLL) and Small Lymphocytic Lymphoma (SLL) indications and will required be for new patient starts. The offeror must make all package sizes for the eligible strengths available. All proposed/awarded package sizes will be awarded at the same price per capsule/tablet. Note: NDC is defined as National Drug Code. NDA is defined as New Drug Application. Line Item 1A Ibrutinib Capsules (140 MG) NDC # __________________ NDA#_________________ Units per package: ___________ Schedule of Supplies Number of Patients Units per Day Unit (Capsule) Price Cost per Day (Unit Price x 3 units per day) Annual Total (Cost per Day x 2,444 patients x 365) Base Year 2,444 3 Option Year One 2,444 3 Option Year Two 2,444 3 Option Year Three 2,444 3 Option Year Four 2,444 3 Alternate Package Size (if applicable): NDC # __________________ Units per package: ___________ OR Line Item 1B Acalabrutinib Tablets (100 MG) NDC # __________________ NDA#_________________ Units per package: ___________ Schedule of Supplies Number of Patients Units per Day Unit (Tablet) Price Cost per Day (Unit Price x 2 units per day) Annual Total (Cost per Day x 2,444 patients x 365) Base Year 2,444 2 Option Year One 2,444 2 Option Year Two 2,444 2 Option Year Three 2,444 2 Option Year Four 2,444 2 Alternate Package Size (if applicable): NDC # __________________ Units per package: ___________ OR Line Item 1C Zanubrutinib Capsules (80 MG) NDC # __________________ NDA#_________________ Units per package: ___________ Schedule of Supplies Number of Patients Units per Day Unit (Capsule) Price Cost per Day (Unit Price x 4 units per day) Annual Total (Cost per Day x 2,444 patients x 365) Base Year 2,444 4 Option Year One 2,444 4 Option Year Two 2,444 4 Option Year Three 2,444 4 Option Year Four 2,444 4 Alternate Package Size (if applicable): NDC # __________________ Units per package: ___________

Inactive

Pre-solicitation Notice The VA National Acquisition Center intends to issue Request for Proposal (RFP) 36E79724R0007 for an unrestricted procurement for Bruton Tyrosine Kinase (BTK) Inhibitors for the... Pre-solicitation Notice The VA National Acquisition Center intends to issue Request for Proposal (RFP) 36E79724R0007 for an unrestricted procurement for Bruton Tyrosine Kinase (BTK) Inhibitors for the Department of Veterans Affairs (VA), Bureau of Prisons (BOP), and Indian Health Service (IHS). The VA will award one contract to the responsible offeror who will be able to provide an uninterrupted source of supply for the contracted item. The contract period will be for one year plus four pre-priced one-year option periods. The contract items will be distributed through the VA s Pharmaceutical Prime Vendor Program. Offerors must state the exact name (name that appears on label) by which the drug will be supplied and have an NDC or UPC number that is unique to the offeror. Solicitation # 36E79724R0007 will be electronically issued in commercial item format in accordance with FAR Part 12 on or about February 8, 2024, with a tentative closing date of February 22, 2024. The NAICS code for this procurement is 325412. Any future amendments and other miscellaneous documents will be available electronically for download at the following URL: https://sam.gov. No paper copies of the solicitation will be available, and no telephone requests for paper copies of the solicitation will be accepted. Interested offerors are advised to continuously check this URL for any changes to this solicitation. All responsible sources may submit an offer that if timely received, will be considered. The point of contact for this procurement is Ray Roldan. Questions can be e-mailed to: Raymond.roldan@va.gov. The estimated annual requirements are as follows: Item Description Units (Tablets or Capsules) per Day Total For New Patients 1A Ibrutinib Capsules 140MG 3 2,444 OR OR OR OR 1B Acalabrutinib Tablets 100MG 2 2,444 OR OR OR OR 1C Zanubrutinib Capsules 80MG 4 2,444 The price evaluation will be completed by multiplying the proposed BTK Inhibitors price by the number of units per day required per patient to calculate a cost per day. This cost per day will then be multiplied by the estimated number of patients (a total of 2,444 for all participating agencies) for the proposed product and 365 (days per year) to calculate a total cost per year. The required number of units per patient per day are listed in the table above for each item (1A, 1B, 1C). The offeror must make all package sizes for the eligible strengths available. All proposed/awarded package sizes will be awarded at the same price per capsule/tablet. The awarded product will be the only agent listed on the VA National Formulary for Chronic Lymphocytic Leukemia (CLL) and Small Lymphocytic Lymphoma (SLL) indications and will required be for new patient starts. Patients already taking one of the versions not awarded are not mandated to be switched over to the awarded version and are not included in the annual estimates above. However, patients currently taking a version that is not awarded may be switched over to the awarded version for clinical reasons.